Recovery from Respiratory Failure in Patients with Coronavirus Disease 2019
OBJECTIVE: Coronavirus disease 2019 (COVID-19) can cause hypoxic respiratory failure; long-term oxygen therapy (LTOT) duration is unknown.
MATERIAL AND METHODS: The aim was to investigate which patients would need LTOT after COVID-19 pneumonia. This single-center, prospective study was conducted at the Ankara University Faculty of Medicine, Department of Chest Diseases, between May 2021 and December 2021. The 70 patients hospitalized for COVID-19 pneumonia and discharged with LTOT due to hypoxemic respiratory failure were included. Patients were divided into 2 groups as group I (LTOT requirement <3 months) and group II (LTOT requirement continued ≥3 months).
RESULTS: The mean age was 64.4 ± 13.5 years, and 44 (62.9%) of them were male. The most frequently encountered comorbidities were cardiovascular disease (57.1%) and lung disease (22.9%). While PaO2 levels increased in both groups during the follow-up period, this increment was significantly higher in group I (PaO2: 66.6 ± 9.9 mm Hg, P < .001). The factors affecting the LTOT requirement were evaluated using binary logistic regression. On multivariate analyses of lymphocytes, ferritin, C-reactive protein, PaO2, SaO2, subpleural reticulation, and number of lobes affected (≥3 lobes), the SaO2 level and presence of subpleural reticulation were significantly different between the 2 groups [odds ratio (OR) (95% CI): 0.853 (0.749-0.971), P = .016] and [OR (95% CI): 0.171 (0.042-0.733), P = .017], respectively.
CONCLUSION: A significant proportion of patients who develop respiratory failure due to COVID-19 recover within the first 3 months. Factors determining the LTOT requirement for more than 3 months were SaO2 and the presence of subpleural reticulation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
Thoracic research and practice - (2023) vom: 28. Nov. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Öz, Miraç [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 28.11.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.5152/ThoracResPract.2023.23001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365063495 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365063495 | ||
| 003 | DE-627 | ||
| 005 | 20231226100858.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.5152/ThoracResPract.2023.23001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1216.xml |
| 035 | |a (DE-627)NLM365063495 | ||
| 035 | |a (NLM)38015163 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Öz, Miraç |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Recovery from Respiratory Failure in Patients with Coronavirus Disease 2019 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 28.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a OBJECTIVE: Coronavirus disease 2019 (COVID-19) can cause hypoxic respiratory failure; long-term oxygen therapy (LTOT) duration is unknown | ||
| 520 | |a MATERIAL AND METHODS: The aim was to investigate which patients would need LTOT after COVID-19 pneumonia. This single-center, prospective study was conducted at the Ankara University Faculty of Medicine, Department of Chest Diseases, between May 2021 and December 2021. The 70 patients hospitalized for COVID-19 pneumonia and discharged with LTOT due to hypoxemic respiratory failure were included. Patients were divided into 2 groups as group I (LTOT requirement <3 months) and group II (LTOT requirement continued ≥3 months) | ||
| 520 | |a RESULTS: The mean age was 64.4 ± 13.5 years, and 44 (62.9%) of them were male. The most frequently encountered comorbidities were cardiovascular disease (57.1%) and lung disease (22.9%). While PaO2 levels increased in both groups during the follow-up period, this increment was significantly higher in group I (PaO2: 66.6 ± 9.9 mm Hg, P < .001). The factors affecting the LTOT requirement were evaluated using binary logistic regression. On multivariate analyses of lymphocytes, ferritin, C-reactive protein, PaO2, SaO2, subpleural reticulation, and number of lobes affected (≥3 lobes), the SaO2 level and presence of subpleural reticulation were significantly different between the 2 groups [odds ratio (OR) (95% CI): 0.853 (0.749-0.971), P = .016] and [OR (95% CI): 0.171 (0.042-0.733), P = .017], respectively | ||
| 520 | |a CONCLUSION: A significant proportion of patients who develop respiratory failure due to COVID-19 recover within the first 3 months. Factors determining the LTOT requirement for more than 3 months were SaO2 and the presence of subpleural reticulation | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Erol, Serhat |e verfasserin |4 aut | |
| 700 | 1 | |a Gürün Kaya, Aslıhan |e verfasserin |4 aut | |
| 700 | 1 | |a Işık, Özlem |e verfasserin |4 aut | |
| 700 | 1 | |a Çiftci, Fatma |e verfasserin |4 aut | |
| 700 | 1 | |a Çınar, Güle |e verfasserin |4 aut | |
| 700 | 1 | |a Uzun, Çağlar |e verfasserin |4 aut | |
| 700 | 1 | |a Azap, Alpay |e verfasserin |4 aut | |
| 700 | 1 | |a Çiledağ, Aydın |e verfasserin |4 aut | |
| 700 | 1 | |a Kaya, Akın |e verfasserin |4 aut | |
| 700 | 1 | |a Özdemir Kumbasar, Özlem |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Thoracic research and practice |d 2023 |g (2023) vom: 28. Nov. |w (DE-627)NLM359859445 |x 2979-9139 |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:28 |g month:11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.5152/ThoracResPract.2023.23001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 28 |c 11 | ||